Table 5 Lipid modifying therapy by total and all high risk population and respective high risk group.
Total (n = 5361) | All high risk (n = 2013) | T2DM (n = 1237) | CHD (n = 518) | 10 year CHD risk > 20% (n = 258) | |
|---|---|---|---|---|---|
Statins alone | 93.6% | 93.8% | 92.5% | 96.3% | 95.0% |
Fibrates alone | 5.3% | 5.8% | 7.1% | 2.9% | 5.0% |
Other monotherapy | 0.9% | 0.2% | 0.2% | 0.4% | 0.0% |
Combinations and other | 0.3% | 0.2% | 0.2% | 0.4% | 0.0% |